Abstract: Cancer-related hypertension (CR-HTN) is a common and significant clinical issue in cancer patients, leading to poor prognosis. However, there is still a lack of unified understanding and standardized management for this condition. The Society of Integrative Cardio-Oncology, China Anti-Cancer Association, has developed this consensus based on clinical research evidence and practical experience. It provides a detailed overview of the epidemiology, pathogenesis, diagnosis and differential diagnosis, treatment, prognosis, and follow-up of CR-HTN. The consensus advocates for a proactive blood pressure monitoring strategy to detect CR-HTN early and recommends an integrated approach combining anti-hypertensive and anti-cancer therapies to standardize the management of CR-HTN, thereby improving the diagnosis and treatment levels of CR-HTN in China.